Scholar Rock earnings beat by $0.03, revenue fell short of estimates

Scholar Rock (SRRK) reported Q3 EPS of -$0.81, beating estimates by $0.03, but revenue of $570K missed expectations of $1.43M. The stock is down 1.85% over 3 months but up 67.42% year-over-year. InvestingPro rates its financial health as 'fair performance'.

Original reporting
Published Nov 10, 2026, 12:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SRRK
Neutral
medium confidence
Mentioned
$SRRK
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

The earnings release provides the first public data on Q3 performance, offering traders fresh information on the company's financial health.

02

Market read

The report is a primary disclosure for a small-cap biotech, offering limited but actionable insight for niche investors.

03

What to watch

Cash runway and upcoming clinical trial milestones are not discussed but could drive future valuation.

Relevance 6/10Novelty 5/10Timing: post-market release

Background

Scholar Rock is a micro-cap biotech firm listed on NASDAQ, known for its focus on research tools for the life sciences.

Company-level read

Ticker impact

$SRRKNeutralMedium confidence
Context

Scholar Rock reported Q3 EPS of -0.81, beating estimates by $0.03, and revenue of $570K versus $1.43M consensus.

Expected impact

potential modest downside as revenue miss outweighs EPS beat

Evidence & confidence

Small-cap earnings with modest beat on loss per share and a large revenue shortfall typically lead to limited price movement.

Market effects

Limited impact on biotech/clinical trial sector; earnings highlight revenue volatility for early-stage companies.

Primarily affects US micro-cap investors; no broader regional effect.

Minimal global relevance due to company size and niche focus.

Counterpoint

Despite revenue miss, the EPS beat could signal improving cost structure; potential upside if guidance improves.

Key entities

  • Scholar Rock

    NASDAQ-listed biotech firm (SRRK).

Related articles

$SRRKMedAI 8/10

Scholar Rock (SRRK) Q3 2026 Earnings Call Transcript

Scholar Rock (SRRK) reported Q3 2026 earnings, highlighting FDA approval of ISEMBYLD for SMA, a $205M deal for a priority review voucher, and progress in Japan and Phase II FORGE study. ISEMBYLD showed a 2.2-point motor function improvement in trials, with strong early launch demand. The company reported $0.6M in ISEMBYLD revenue and $413.6M in cash, with no immediate need for equity offering.

$SRRKLow

What Scholar Rock (SRRK) Said on Its Q3 Earnings Call

Scholar Rock (SRRK) reported Q3 earnings, noting no demand impact from a bone fracture warning. The company resubmitted its European marketing application for apitegromab, expecting a decision in early 2027. It anticipates a 2027 launch in Japan and Germany. Operating expenses were $106.6M, with $413.6M in cash. SRRK sold a priority review voucher for $205M and has access to an additional $150M under its debt facility.

$SRRKHighAI 8/10

Raymond James reiterates Strong Buy on Scholar Rock stock after Q3 results

Raymond James maintained a Strong Buy rating and $72.00 price target for Scholar Rock (NASDAQ: SRRK) after its Q3 2026 results. The stock is up 17% this week and 76% over the past year. Scholar Rock reported its first product revenues for ISEMBYLD, which received FDA approval in September 2026. The company's EPS beat estimates but revenue missed expectations, falling 60.14% short of forecasts.